ArticlePloS one2011
Up-regulated Dicer expression in patients with cutaneous melanoma.
Article in PloS one, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 66 citations in OpenAlex.
- Risk Factors for Melanoma Survival: DGCR8 as a Predictive Factor for Mortality in Young Patients.Acta dermato-venereologica · 2026Article
- Multiple roles of MicroRNAs in melanoma: biomarkers for diagnosis, prognosis, and treatment prediction.Frontiers in immunology · 2026Review
- Article
- DGCR8 Microprocessor Subunit Mutation and Expression Deregulation in Thyroid Lesions.International journal of molecular sciences · 2022Article
- Article
- Review
- The impact of variations in transcription of DICER and AGO2 on exacerbation of childhood B-cell lineage acute lymphoblastic leukaemia.International journal of experimental pathology · 2019Article
- MOV10 binding circ-DICER1 regulates the angiogenesis of glioma via miR-103a-3p/miR-382-5p mediated ZIC4 expression change.Journal of experimental & clinical cancer research : CR · 2019Article
- New susceptibility loci for cutaneous melanoma risk and progression revealed using a porcine model.Oncotarget · 2018Article
- Identification of microRNAs associated with invasive and aggressive phenotype in cutaneous melanoma by next-generation sequencing.Laboratory investigation; a journal of technical methods and pathology · 2017Article
- DICER governs characteristics of glioma stem cells and the resulting tumors in xenograft mouse models of glioblastoma.Oncotarget · 2016Article
- The modulation of Dicer regulates tumor immunogenicity in melanoma.Oncotarget · 2016Article
- Article
- Association of tumor and plasma microRNA expression with tumor monosomy-3 in patients with uveal melanoma.Clinical epigenetics · 2016Article
- MicroRNA biogenesis pathways in cancer.Nature reviews. Cancer · 2015Review
- Silencing the double-stranded RNA binding protein DGCR8 inhibits ovarian cancer cell proliferation, migration, and invasion.Pharmaceutical research · 2015Article
- microRNAs as Potential Biomarkers in Adrenocortical Cancer: Progress and Challenges.Frontiers in endocrinology · 2015Review
- Single-nucleotide polymorphisms of microRNA processing machinery genes are associated with risk for gastric cancer.OncoTargets and therapy · 2015Article
- Reply to comment on: Strong reduction of AGO2 expression in melanoma and cellular consequences.British journal of cancer · 2014Article
- A dosage-dependent pleiotropic role of Dicer in prostate cancer growth and metastasis.Oncogene · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMicroRNAs (miRNAs) are small non-coding RNAs (18-24 nucleotides) that have recently been shown to regulate gene expression during cancer progression. Dicer, a central enzyme in the multi-component miRNA biogenesis pathway, is involved in cutting precursor miRNAs to functionally mature forms. Emerging evidence shows that Dicer expression is deregulated in some human malignancies and it correlates with tumor progression, yet this role has not yet been investigated in skin cancers. METHODS AND
findingsUsing an anti-human monoclonal antibody against Dicer and immunohistochemistry, we compared the expression of Dicer protein among 404 clinically annotated controls and skin tumors consisting of melanocytic nevi (n = 71), a variety of melanomas (n = 223), carcinomas (n = 73) and sarcomas (n = 12). Results showed a cell-specific up-regulated Dicer in 81% of cutaneous, 80% of acrolentiginous and 96% of metastatic melanoma specimens compared to carcinoma or sarcoma specimens (P<0.0001). The expression of Dicer was significantly higher in melanomas compared to benign melanocytic nevi (P<0.0001). In patients with cutaneous melanomas, Dicer up-regulation was found to be significantly associated with an increased tumor mitotic index (P = 0.04), Breslow's depth of invasion (P = 0.03), nodal metastasis (P = 0.04) and a higher American Joint Committee on Caner (AJCC) clinical stage (P = 0.009). Using western blot analysis, we confirmed the cell-specific up-regulation of Dicer protein in vitro. A pooled-analysis on mRNA profiling in cutaneous tumors showed up-regulation of Dicer at the RNA level in cutaneous melanoma, also showing deregulation of other enzymes that participate in the biogenesis and maturation of canonical miRNAs.
conclusionsIncreased Dicer expression may be a clinically useful biomarker for patients with cutaneous melanoma. Understanding deregulation of Dicer and its influence on miRNA maturation is needed to predict the susceptibility of melanoma patients to miRNA-based therapy in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.